CC 930
- Product Name
- CC 930
- CAS No.
- 899805-25-5
- Chemical Name
- CC 930
- Synonyms
- CC930;CC 930;MCC930;CC-930;CS-1152;Tanziser;Tanzisertib;CC-930(Tanzisertib);TANZISERTIB (CC-930);TANZISERTIB; CC930; CC 930
- CBNumber
- CB12666607
- Molecular Formula
- C21H23F3N6O2
- Formula Weight
- 448.44
- MOL File
- 899805-25-5.mol
CC 930 Property
- Boiling point:
- 626.4±65.0 °C(Predicted)
- Density
- 1.63±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
- form
- Powder
- pka
- 15.05±0.40(Predicted)
- color
- Off-white to yellow
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
- Precautionary statements
-
P280Wear protective gloves/protective clothing/eye protection/face protection.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- 22466
- Product name
- CC-930
- Purity
- ≥98%
- Packaging
- 1mg
- Price
- $36
- Updated
- 2024/03/01
- Product number
- 22466
- Product name
- CC-930
- Purity
- ≥98%
- Packaging
- 5mg
- Price
- $155
- Updated
- 2024/03/01
- Product number
- 22466
- Product name
- CC-930
- Purity
- ≥98%
- Packaging
- 10mg
- Price
- $274
- Updated
- 2024/03/01
- Product number
- 22466
- Product name
- CC-930
- Purity
- ≥98%
- Packaging
- 25mg
- Price
- $595
- Updated
- 2024/03/01
- Product number
- T007100
- Product name
- Tanzisertib
- Packaging
- 5mg
- Price
- $150
- Updated
- 2021/12/16
CC 930 Chemical Properties,Usage,Production
Uses
Tanzisertib is a potent, selective, and orally active c-Jun amino-terminal kinase (JNK) inhibitor used for treatment of dermal fibrosis.
Biological Activity
Tanzisertib (CC-930, JNK-930, JNKI-1) has an ATP-competitive inhibitory effect on the phosphorylation of the JNK-dependent protein substrate c-Jun and all isoforms of JNK (Ki(JNK1) = 44 ± 3 nM, IC50(JNK1) = 61 nM, Ki(JNK2) = 6.2 ± 0.6 nM, IC50(JNK2) = 5 nM, IC50(JNK3) = 5 nM), selective inhibition of ERK1 and p38a with IC50 of 0.48 μM and 3.4 μM, respectively .
in vivo
In the acute PK-PD rat model of LPS-induced TNFα production, oral administration of 10 mg/kg and 30 mg/kg of CC-930 reduced the production of TNFα in vivo by 23% and 77%, respectively. CC-930 is well tolerated in vivo and its effect is proportional to dose.
target
Target | Value |
JNK3 (Cell-free assay) | 0.006 μM |
JNK2 (Cell-free assay) | 0.007 μM |
0.061 μM |
CC 930 Preparation Products And Raw materials
Raw materials
Preparation Products
CC 930 Suppliers
- Tel
- 00852-68527855
- Fax
- 00852-26406298
- info@itopbiochem.com
- Country
- China Hong Kong
- ProdList
- 902
- Advantage
- 58